Clinical Trials

MainTitle

Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis

This study has been completed
Sponsor
South East Asia Research Collaboration with Hawaii

Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Information provided by (Responsible Party)
Nittaya Phanuphak, MD, PhD, South East Asia Research Collaboration with Hawaii

ClinicalTrials.gov Identifier
NCT02750059

First received: May 30, 2015
Last updated: September 17, 2019
Last Verified: September 2019
History of Changes
Purpose

Purpose

Primary objective: To compare telmisartan therapy + antiretroviral therapy (ART) versus ART alone during acute Human Immunodeficiency Virus (HIV)a infection in reducing systemic immune activation and trafficking of activated and HIV-infected cells to the central nervous system (CNS), and limiting establishment and persistence of the CNS reservoir of HIV.

At 48 weeks (during the telmisartan therapy) and 72 weeks (~6 months after cessation of telmisartan augmentation), the investigator expect subjects in the telmisartan group will have reduced levels of blood and CSF immune activation markers, reduced brain inflammation, lower CSF HIV ribonecleic acid (RNA) and improved neuropsychological testing performance.

Secondary objective: In subjects who are willing to undergo the optional inguinal lymph node biopsy, the study will determine whether subjects receiving telmisartan plus ART for 48 weeks develop less lymphoid tissue fibrosis than subjects receiving ART alone for 48 weeks.

Subject population: Male and female subjects age ≥ 18 years old with acute HIV infection who are identified and enrolled in SEARCH 010/RV254 protocol will be asked to co-enroll in this study.

Number of subjects: 21

Duration of follow-up: 72 weeks

Study design: 21 acutely HIV-infected subjects will be randomized 2:1 to treatment with telmisartan + ART (n=14) vs. ART alone (n=7) for the first 48 weeks followed by ART alone in both arms to week 72. Blood and CSF, magnetic resonance imaging (MRI), and neuropsychological testing and exam will be collected at baseline, week 48 and week 72. Inguinal lymph node biopsy is an optional procedure that will be offered at baseline and week 48.

Condition Intervention Phase
Acute HIV Infection
HIV CNS Involvement

Drug : TDF/3TC/EFV + Telmisartan
Drug : TDF/3TC/EFV only
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of CNS Reservoirs of HIV and Lymph Node Fibrosis

Further study details as provided by Nittaya Phanuphak, MD, PhD, South East Asia Research Collaboration with Hawaii:

Primary Outcome Measures

  • Difference between study arms at weeks 48 and 72 in CSF neopterin [ Time Frame: 48 and 72 weeks ]
Secondary Outcome Measures:
  • Difference between study arms in lymphoid tissue fibrosis at week 48 [ Time Frame: 48 weeks ]
  • Difference between study arms at weeks 48 and 72 in brain inflammation by magnetic resonance spectroscopy (MRS) [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in CSF HIV RNA by single copy assay [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in aggregate neuropsychological testing performance score (NPZ-4) on Grooved Pegboard, Color Trails 1, Color Trails 2 and Trail Making A [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in CSF monocyte chemoattractant protein-1 (MCP-1) levels [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in CSF interferon-gamma-inducible protein-10 (IP-10) levels [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in plasma neopterin levels [ Time Frame: 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in plasma soluable CD14 (sCD14) levels [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in plasma interleukin-6 (IL-6) levels [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in plasma D-dimer levels [ Time Frame: 48 and 72 weeks ]
  • Difference between study arms at weeks 48 and 72 in plasma soluable CD163 (sCD163) levels [ Time Frame: 48 and 72 weeks ]

Enrollment: 21
Study Start Date: January 2015
Study Completion Date: February 2018
Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: TDF/3TC/EFV + Telmisartan
The subjects will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART
Drug: TDF/3TC/EFV + Telmisartan

The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily

Other Name: tenofovir/lamivudine/efavirenz + Micardis
Active Comparator: TDF/3TC/EFV only
Subjects will receive ART only
Drug: TDF/3TC/EFV only

Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.

Other Name: tenofovir/lamivudine/efavirenz

Detailed Description:

Clinical assessments:
Neurological exam: South East Asia Research Collaboration with Hawaii (SEARCH) employs the AIDS Clinical Trials Group (ACTG)-derived HIV macroneurological examination, a physician rated symptoms assessment of cognitive features typical of HAND and peripheral neuropathy
Neuropsychological assessments: SEARCH employs the HIV neurocognitive battery originally developed by Maj et al. designed to minimize cultural bias and tested in Bangkok. All subjects will have the full SEARCH battery as previously published, avoiding evaluations following invasive procedures.
Quantification of Drug use: Drug and alcohol use are assessed with a structured interview including methamphetamine, heroin, and marijuana based on a Thai Red Cross study defining frequently abused drugs in Bangkok. Urine is stored at each visit and may be later tested for illicit drugs. Evidence of intoxication is documented so that neuropsychological data can be censored.
Lumbar punctures are completed per standard clinical procedures using a Sprotte® (pencil-point) needle to minimize complications. Standard assessments of CSF and serum, protein and cell count are completed and approximately 20cc are collected and ultra-centrifuged, Cell pellets of both blood and CSF will be cryopreserved for future potential studies, with subject consent. Supernatants are divided into 0.5cc aliquots, and frozen to -80oC on the same day. Venereal Disease Research Laboratory test (VDRL)/Rapid Plasma Reagin (RPR) will be assessed at baseline and in follow up if risk for new syphilis exposure is reported. Participant hospitalization for hydration will be completed, if needed. Participants will be compensated for their time based on Institutional Review Board (IRB)-approved rates.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

    1. Age ≥ 18 years old
    2. Have protocol-defined acute HIV-1 infection (Tested 4th generation HIV enzyme immunoassay [EIA] negative and NAT positive or tested 4th generation HIV EIA positive, negative by less sensitive EIA and nucleic acid testing [NAT] positive)
    3. Be part of the SEARCH 010/RV 254 study
    4. Ability and willingness to start ART immediately after diagnosis
    5. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read to them by a member of the study staff and may then give informed consent by using making a thumb print
    6. Availability for follow-up for the duration of the planned study
    7. Systolic blood pressure ≥ 110 mmHg
    8. Agree to undergo lumbar puncture at weeks 0, 48 and 72
    9. Ability and willingness to provide informed consent


Exclusion Criteria:
    1. Pregnancy (current or within the last 6 months) or breastfeeding
    2. Uncontrolled hypertension
    3. Use of thiazolidinediones or other angiotensin receptor blockers class [losartan, irbesartan, olmesartan, valsartan, candesartan (washout permitted)]
    4. Screening laboratory values: absolute neutrophil count (ANC) < 750 cells/mm3, hemoglobin <10 gm/dL creatinine clearance<30mL/min (estimated by the Cockcroft-Gault equation using ideal body weight)
    5. Known renal artery stenosis
    6. Known cirrhosis or severe liver disease
    7. Unstable coronary artery disease/angina or decompensated congestive heart failure
    8. Any history of intolerance to any angiotensin II receptor blocker (ARB)
    9. Need for ongoing potassium supplementation
    10. Any contraindication to lumbar puncture such as history of bleeding diathesis or known
    cerebral mass lesion

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02750059

Locations

Thailand
SEARCH Thailand
Bangkok, Thailand, 10330

Sponsors and Collaborators

South East Asia Research Collaboration with Hawaii
National Institute of Neurological Disorders and Stroke (NINDS)

Investigators

Principal Investigator: Nittaya Phanuphak, MD, PhD South East Asia Research Collaboration with Hawaii
More Information

More Information


Responsible Party: Nittaya Phanuphak, MD, PhD, Nittaya Phanuphak, MD, PhD, South East Asia Research Collaboration with Hawaii  
ClinicalTrials.gov Identifier: NCT02750059   History of Changes  
Other Study ID Numbers: SEARCH 018  
  1R01NS084911-01  
Study First Received: May 30, 2015  
Last Updated: September 17, 2019  
Individual Participant Data    
Plan to Share IPD: Undecided  

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Tenofovir
Lamivudine
Efavirenz
Telmisartan

ClinicalTrials.gov processed this data on December 13, 2019
This information is provided by ClinicalTrials.gov.